.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A11C_VitaminAAndDInclCombinationsOfTheTwo.A11CC06_Calcifediol.Calcifediol .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A11C_VitaminAAndDInclCombinationsOfTheTwo.A11CC06_Calcifediol.Calcifediol| name: | Calcifediol |
| ATC code: | A11CC06 | route: | oral |
| n-compartments | 2 |
Calcifediol (25-hydroxyvitamin D3) is an intermediate metabolite of vitamin D3, used in the treatment of vitamin D deficiency and certain disorders involving impaired vitamin D metabolism, such as chronic kidney disease. It is approved and used in several countries for these indications.
Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.
Ocampo-Pelland, AS, et al., & Riggs, MM (2017). Model-based meta-analysis for comparing Vitamin D2 and D3 parent-metabolite pharmacokinetics. Journal of pharmacokinetics and pharmacodynamics 44(4) 375–388. DOI:10.1007/s10928-017-9525-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28466367
Tuey, SM, et al., & Joy, MS (2024). Population Pharmacokinetic Model of Vitamin D. International journal of molecular sciences 25(22) –. DOI:10.3390/ijms252212279 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39596344
Hsu, S, et al., & de Boer, IH (2021). Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. Journal of the American Society of Nephrology : JASN 32(1) 188–198. DOI:10.1681/ASN.2020050625 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33115916